ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

Novartis licenses diabetes treatment

by Michael McCoy
April 24, 2017 | APPEARED IN VOLUME 95, ISSUE 17

Novartis has licensed rights to a type 1 diabetes drug being developed by Parvus Therapeutics, which makes nanomedicines to halt or reverse autoimmune diseases. Parvus’s diabetes products, called T1D Navacims, are formed by conjugating iron oxide nanoparticles with copies of a peptide derived from a pancreatic autoantigen. Navacims reprogram pathogenic T cells into beneficial cells that suppress autoimmune-disease-causing immune cells.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment